Skip to main
PHGE

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX is a company poised for success as they continue to make progress on their lead assets, BX211 and BX004, which target severe infections in cystic fibrosis and diabetic foot osteomyelitis patients, respectively. The recent positive news from the independent DMC, the resolution of the FDA's hold on the BX004 Phase 2b program, and ongoing recruitment in their BX004 trial highlight the company's potential for success. Additionally, the FDA's guidance on DFI studies provides a clear path for BiomX's development plans and the company's strong financial position and EPS beating their estimates show their capability for sustainable growth.

Bears say

BiomX is a high-risk investment with a negative outlook due to potential challenges in securing funding for its drug development and the risk of failed or inconclusive clinical trials. While the FDA has shown flexibility and support for the company's clinical programs, there is no guarantee of success. Additionally, upcoming dilutive capital raises may negatively impact the stock. However, if the company is able to achieve its projected market penetration and secure partnerships, there is potential for upside to our $26 price target based on the company's two lead phage assets, as well as the potential for additional indications and ex-U.S. opportunities. Overall, the stock remains a speculative investment with significant potential risks.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.